Valion Bio (VBIO) Liabilities and Shareholders Equity (2021 - 2026)

Valion Bio has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $32.5 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 620.34% year-over-year to $32.5 million in Q2 2026; TTM through Jun 2026 was $74.8 million, a 416.48% increase from a year earlier, with the FY2025 full-year figure at $31.6 million, up 1026.01% from the prior year.
• Liabilities and Shareholders Equity was $32.5 million for Q2 2026 at Valion Bio, up from $31.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $32.5 million in Q2 2026, with the low at $2.8 million in Q4 2024.
• Average Liabilities and Shareholders Equity over 5 years is $9.1 million, with a median of $5.9 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity plunged 60.93% in 2022, then soared 1026.01% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $5.9 million in 2022, then fell by 12.22% to $5.2 million in 2023, then plunged by 45.57% to $2.8 million in 2024, then jumped by 1026.01% to $31.6 million in 2025, then climbed by 2.74% to $32.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $32.5 million (Q2 2026), $31.6 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.